Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director · Bd. Co-Chair, President & CSO | December 31, 2025 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 31, 2025 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 310,460 |
Ending reported balance
After 2025-12-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-31 · Exercise / conversion · Acquired 28,570 · Balance 339,030 Row 2 · 2025-12-31 · Tax withholding · Disposed 28,570 · Balance 310,460 |
| 2020 Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 595,077 |
Reported balance
After 2025-12-31 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-12-31 · Exercise / conversion · Disposed 28,570 · Balance 595,077 F2: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company. |
| Common StockSEC Table I · non-derivative | IndirectBy 2024 GRAT | 71,487 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 71,487 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT | 200,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 200,000 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT II | 200,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 200,000 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 5,962 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,962 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust for Chldn. | 180,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 180,000 F1: As investment trustee of trusts for the benefit of the reporting person's children. |
| Common StockSEC Table I · non-derivative | Indirectby 2024 GRAT II | 101,988 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 101,988 |
| Common StockSEC Table I · non-derivative | Indirectby Children | 56,048 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 56,048 |
Filing footnotes · ownership attribution and instrument terms
F1: As investment trustee of trusts for the benefit of the reporting person's children.
F2: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2024 Filed Jan 4, 2024 21:20 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 16,848 | $900.00 | $15,163,200.00 |
DisclosureSEC source: 0001883850-24-000007 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 180,000 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022. F2 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| January 02, 2024 Filed May 1, 2024 20:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 16,848 | $900.00 | $15,163,200.00 |
DisclosureSEC source: 0001883850-24-000012 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 180,000 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022. F2 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversion2019 Performance Stock Units · Derivative | 25,155 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001883850-23-000095 · edgardoc.xml · derivative · entry 7 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,155 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On December 11, 2019, the reporting person was granted performance-based restricted stock units ("PSUs") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return ("TSR") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended. F1 · price: On December 11, 2019, the reporting person was granted performance-based restricted stock units ("PSUs") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return ("TSR") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended. F1 · derivative.exercise_date: On December 11, 2019, the reporting person was granted performance-based restricted stock units ("PSUs") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return ("TSR") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended. F1 · derivative.expiration_date: On December 11, 2019, the reporting person was granted performance-based restricted stock units ("PSUs") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return ("TSR") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 12,841 | $844.09 | $10,838,959.69 |
DisclosureSEC source: 0001883850-23-000095 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 752,486 Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 25,155 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001883850-23-000095 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · Bd. Co-Chair, President & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 765,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On December 11, 2019, the reporting person was granted performance-based restricted stock units ("PSUs") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return ("TSR") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 20:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $810.30 | $324,120.00 |
DisclosureSEC source: 0001883850-23-000062 · edgardoc.xml · nonDerivative · entry 8 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Plan reported Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 196,848 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022. F3 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 20:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 700 | $806.47 | $564,529.00 |
DisclosureSEC source: 0001883850-23-000062 · edgardoc.xml · nonDerivative · entry 7 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Plan reported Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 197,248 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022. F3 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 20:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 47 | $805.55 | $37,860.85 |
DisclosureSEC source: 0001883850-23-000062 · edgardoc.xml · nonDerivative · entry 6 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Plan reported Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 197,948 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022. F3 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 20:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 254 | $804.38 | $204,312.52 |
DisclosureSEC source: 0001883850-23-000062 · edgardoc.xml · nonDerivative · entry 5 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Plan reported Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 197,995 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022. F7 · price: Represents volume-weighted average price of sales of 254 shares of Company stock on March 23, 2023 at prices ranging from $804.00 to $804.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price. F3 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 20:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 642 | $803.30 | $515,718.60 |
DisclosureSEC source: 0001883850-23-000062 · edgardoc.xml · nonDerivative · entry 4 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Plan reported Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 198,249 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022. F6 · price: Represents volume-weighted average price of sales of 642 shares of Company stock on March 23, 2023 at prices ranging from $803.01 to $803.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price. F3 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 20:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,237 | $802.54 | $992,741.98 |
DisclosureSEC source: 0001883850-23-000062 · edgardoc.xml · nonDerivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Plan reported Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 198,891 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022. F5 · price: Represents volume-weighted average price of sales of 1,237 shares of Company stock on March 23, 2023 at prices ranging from $802.00 to $802.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price. F3 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 20:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 122 | $801.16 | $97,741.52 |
DisclosureSEC source: 0001883850-23-000062 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Plan reported Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 200,128 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022. F4 · price: Represents volume-weighted average price of sales of 122 shares of Company stock on March 23, 2023 at prices ranging from $801.00 to $801.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price. F3 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 20:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 254 | $800.59 | $203,349.86 |
DisclosureSEC source: 0001883850-23-000062 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Plan reported Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 200,250 F1 · kind: Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022. F2 · price: Represents volume-weighted average price of sales of 254 shares of Company stock on March 23, 2023 at prices ranging from $800.52 to $800.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price. F3 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:15 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 13,189 | $800.08 | $10,552,255.12 |
DisclosureSEC source: 0001883850-23-000044 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 200,504 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 13,189 shares of Company stock on February 6, 2023 at prices ranging from $800.00 to $800.48. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price. F3 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 203,204 | $0.00 Strike: $270.43 | $0.00 |
DisclosureSEC source: 0001883850-21-000034 · edgardoc.xml · derivative · entry 8 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 203,204 shares Expires 2023-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 239,063 | $0.00 Strike: $179.13 | $0.00 |
DisclosureSEC source: 0001883850-21-000034 · edgardoc.xml · derivative · entry 7 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 239,063 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 150,182 | $610.04 | $91,617,027.28 |
DisclosureSEC source: 0001883850-21-000034 · edgardoc.xml · nonDerivative · entry 4 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,019,653 Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 203,204 | $270.43 | $54,952,457.72 |
DisclosureSEC source: 0001883850-21-000034 · edgardoc.xml · nonDerivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,169,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 159,915 | $610.04 | $97,554,546.60 |
DisclosureSEC source: 0001883850-21-000034 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 966,631 Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 239,063 | $179.13 | $42,823,355.19 |
DisclosureSEC source: 0001883850-21-000034 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,126,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,302 | $626.10 | $1,441,282.20 |
DisclosureSEC source: 0001708138-21-000055 · edgardoc.xml · nonDerivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887,483 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 2,302 shares of Company stock on August 16, 2021 at prices ranging from $626.00 to $626.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 46,925 | $625.25 | $29,339,856.25 |
DisclosureSEC source: 0001708138-21-000055 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 889,785 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 46,925 shares of Company stock on August 16, 2021 at prices ranging from $625.00 to $625.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 20:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 773 | $625.00 | $483,125.00 |
DisclosureSEC source: 0001708138-21-000055 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 936,710 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 50,000 | $600.06 | $30,003,000.00 |
DisclosureSEC source: 0001708138-21-000044 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 937,483 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 50,000 shares of Company stock on August 5, 2021 at prices ranging from $600.00 to $600.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2021 at each separate price. Read SEC document |
| June 24, 2021 Filed Aug 6, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 211,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000044 · edgardoc.xml · nonDerivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · by 2019 GRAT Disclosed balance after: 0 Read SEC document |
| June 24, 2021 Filed Aug 6, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 211,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000044 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 213,693 F3 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,276 | $543.13 | $1,236,163.88 |
DisclosureSEC source: 0001708138-21-000026 · edgardoc.xml · nonDerivative · entry 13 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 2,108 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 2,276 shares of Company stock on June 21, 2021 at prices ranging from $543.01 to $543.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price. F1 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10,514 | $542.43 | $5,703,109.02 |
DisclosureSEC source: 0001708138-21-000026 · edgardoc.xml · nonDerivative · entry 12 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 4,384 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 10,514 shares of Company stock on June 21, 2021 at prices ranging from $542.00 to $542.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price. F1 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 19,911 | $541.44 | $10,780,611.84 |
DisclosureSEC source: 0001708138-21-000026 · edgardoc.xml · nonDerivative · entry 11 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 14,898 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 19,911 shares of Company stock on June 21, 2021 at prices ranging from $541.00 to $541.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price. F1 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8,099 | $540.61 | $4,378,400.39 |
DisclosureSEC source: 0001708138-21-000026 · edgardoc.xml · nonDerivative · entry 10 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 34,809 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 8,099 shares of Company stock on June 21, 2021 at prices ranging from $540.00 to $540.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price. F1 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,306 | $539.66 | $1,784,115.96 |
DisclosureSEC source: 0001708138-21-000026 · edgardoc.xml · nonDerivative · entry 9 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 42,908 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 3,306 shares of Company stock on June 21, 2021 at prices ranging from $539.14 to $539.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price. F1 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,868 | $538.54 | $2,621,612.72 |
DisclosureSEC source: 0001708138-21-000026 · edgardoc.xml · nonDerivative · entry 8 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 46,214 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 4,868 shares of Company stock on June 21, 2021 at prices ranging from $538.01 to $538.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price. F1 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6,636 | $537.61 | $3,567,579.96 |
DisclosureSEC source: 0001708138-21-000026 · edgardoc.xml · nonDerivative · entry 7 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 51,082 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 6,636 shares of Company stock on June 21, 2021 at prices ranging from $537.05 to $537.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price. F1 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,768 | $536.37 | $2,021,042.16 |
DisclosureSEC source: 0001708138-21-000026 · edgardoc.xml · nonDerivative · entry 6 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 57,718 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 3,768 shares of Company stock on June 21, 2021 at prices ranging from $536.02 to $536.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price. F1 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,154 | $535.63 | $2,225,007.02 |
DisclosureSEC source: 0001708138-21-000026 · edgardoc.xml · nonDerivative · entry 5 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 61,486 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 4,154 shares of Company stock on June 21, 2021 at prices ranging from $535.05 to $535.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price. F1 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8,236 | $534.48 | $4,401,977.28 |
DisclosureSEC source: 0001708138-21-000026 · edgardoc.xml · nonDerivative · entry 4 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 65,640 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 8,236 shares of Company stock on June 21, 2021 at prices ranging from $534.01 to $534.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price. F1 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7,494 | $533.66 | $3,999,248.04 |
DisclosureSEC source: 0001708138-21-000026 · edgardoc.xml · nonDerivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 73,876 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 7,494 shares of Company stock on June 21, 2021 at prices ranging from $533.14 to $533.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price. F1 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 738 | $532.89 | $393,272.82 |
DisclosureSEC source: 0001708138-21-000026 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 81,370 F2 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 738 shares of Company stock on June 21, 2021 at prices ranging from $532.56 to $532.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price. F1 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| April 15, 2021 Filed Jun 23, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftClass A Stock · Derivative | 5,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000026 · edgardoc.xml · derivative · entry 20 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Son Disclosed balance after: 5,383 Underlying: Common Stock · 5,383 shares Expires not disclosed F15 · derivative.exercise_price: Class A Stock of Regeneron Pharmaceuticals, Inc. ("Regeneron") converts to Common Stock of Regeneron on a one-to-one basis upon certain events or upon election of the shareholder. F16 · derivative.exercise_date: These shares of Class A Stock are presently convertible and such conversion feature does not expire. F16 · derivative.expiration_date: These shares of Class A Stock are presently convertible and such conversion feature does not expire. F17 · ownership.nature: These shares of Class A Stock are held in a trust for the benefit of the reporting person's child, of which the reporting person is trustee. Read SEC document |
| April 15, 2021 Filed Jun 23, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftClass A Stock · Derivative | 5,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000026 · edgardoc.xml · derivative · entry 19 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · by Son Disclosed balance after: 0 Underlying: Common Stock · 5,383 shares Expires not disclosed F15 · derivative.exercise_price: Class A Stock of Regeneron Pharmaceuticals, Inc. ("Regeneron") converts to Common Stock of Regeneron on a one-to-one basis upon certain events or upon election of the shareholder. F16 · derivative.exercise_date: These shares of Class A Stock are presently convertible and such conversion feature does not expire. F16 · derivative.expiration_date: These shares of Class A Stock are presently convertible and such conversion feature does not expire. F18 · ownership.nature: These shares of Class A Stock were held in custody for the benefit of the reporting person's child. Read SEC document |
| April 15, 2021 Filed Jun 23, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftClass A Stock · Derivative | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000026 · edgardoc.xml · derivative · entry 18 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · by Daughter Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires not disclosed F15 · derivative.exercise_price: Class A Stock of Regeneron Pharmaceuticals, Inc. ("Regeneron") converts to Common Stock of Regeneron on a one-to-one basis upon certain events or upon election of the shareholder. F16 · derivative.exercise_date: These shares of Class A Stock are presently convertible and such conversion feature does not expire. F16 · derivative.expiration_date: These shares of Class A Stock are presently convertible and such conversion feature does not expire. F18 · ownership.nature: These shares of Class A Stock were held in custody for the benefit of the reporting person's child. Read SEC document |
| April 15, 2021 Filed Jun 23, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftClass A Stock · Derivative | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000026 · edgardoc.xml · derivative · entry 17 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · By Tr. for Daughter Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires not disclosed F15 · derivative.exercise_price: Class A Stock of Regeneron Pharmaceuticals, Inc. ("Regeneron") converts to Common Stock of Regeneron on a one-to-one basis upon certain events or upon election of the shareholder. F16 · derivative.exercise_date: These shares of Class A Stock are presently convertible and such conversion feature does not expire. F16 · derivative.expiration_date: These shares of Class A Stock are presently convertible and such conversion feature does not expire. F17 · ownership.nature: These shares of Class A Stock are held in a trust for the benefit of the reporting person's child, of which the reporting person is trustee. Read SEC document |
| January 12, 2021 Filed Jun 23, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 82,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000026 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust for Chldn. Disclosed balance after: 82,108 F1 · ownership.nature: As investment trustee of trusts for the benefit of the reporting person's children. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantPerformance Stock Units · Derivative | 620,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-000904 · tm211598-2_4seq1.xml · derivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 620,270 Underlying: Common Stock · 620,270 shares Expires not disclosed F1 · derivative.exercise_price: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain total shareholder return ("TSR") goals derived from compound annual growth rates of 5.6% to 19.2% over a five-year performance period ending on December 31, 2025 (or in some cases at earlier times). Between 50% and 250% of the target number of 248,108 PSUs may be earned upon achievement of such TSR goals but shall only vest at the end of the five-year performance period if the reporting person's service to the Company continues through such date, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change in control ("CIC")). Earned PSUs are subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a CIC. F1 · derivative.exercise_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain total shareholder return ("TSR") goals derived from compound annual growth rates of 5.6% to 19.2% over a five-year performance period ending on December 31, 2025 (or in some cases at earlier times). Between 50% and 250% of the target number of 248,108 PSUs may be earned upon achievement of such TSR goals but shall only vest at the end of the five-year performance period if the reporting person's service to the Company continues through such date, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change in control ("CIC")). Earned PSUs are subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a CIC. F1 · derivative.expiration_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain total shareholder return ("TSR") goals derived from compound annual growth rates of 5.6% to 19.2% over a five-year performance period ending on December 31, 2025 (or in some cases at earlier times). Between 50% and 250% of the target number of 248,108 PSUs may be earned upon achievement of such TSR goals but shall only vest at the end of the five-year performance period if the reporting person's service to the Company continues through such date, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change in control ("CIC")). Earned PSUs are subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a CIC. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 22:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 158,079 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001708138-20-000118 · edgardoc.xml · derivative · entry 9 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 158,079 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: With respect to 240,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 158,079 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 22:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 240,000 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001708138-20-000118 · edgardoc.xml · derivative · entry 8 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,079 Underlying: Common Stock · 240,000 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: With respect to 240,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 158,079 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 22:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 86,096 | $483.25 | $41,605,892.00 |
DisclosureSEC source: 0001708138-20-000118 · edgardoc.xml · nonDerivative · entry 4 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 822,207 Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 22:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 158,079 | $52.03 | $8,224,850.37 |
DisclosureSEC source: 0001708138-20-000118 · edgardoc.xml · nonDerivative · entry 3 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 908,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 22:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 130,714 | $483.25 | $63,167,540.50 |
DisclosureSEC source: 0001708138-20-000118 · edgardoc.xml · nonDerivative · entry 2 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,224 Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 22:30 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 240,000 | $52.03 | $12,487,200.00 |
DisclosureSEC source: 0001708138-20-000118 · edgardoc.xml · nonDerivative · entry 1 YANCOPOULOS GEORGE · CIK 0001226690 · Director · President and Chief Scientific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.